Jazz Pharma buys the only shot at a disease with no FDA treatment

Jazz Pharmaceuticals (JAZZ) just made a bet on a disease that many investors have never heard of. On August 10, the drugmaker agreed to buy privately held Actio Biosciences. The prize is an experimental medicine aimed at a childhood epilepsy so rare, and so severe, that no FDA-approved ...

CryptoAlerta — análise de criptomoedas e mercado em tempo real